allergy protection News
-
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio™ has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that ...
-
Global market for disposable medical supplies to reach nearly $200 billion in 2016
A combination of upgrading and enforcement of infection prevention standards coupled with an expanding volume of hospital, surgical and outpatient procedures will promote overall gains in the global market for disposable medical supplies. Disposable medical gloves, a segment of this market, will continue to flourish despite increasing raw material costs and severe cost-cutting measures in the ...
-
Altamira Therapeutics Provides Update on RNA Therapeutics Program
HAMILTON, BERMUDA / ACCESSWIRE / January 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on its development activities in RNA therapeutics. Growing the Leadership Team As part of its ongoing repositioning around ...
-
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus ...
-
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the "Agreement") for Bentrio™ with Wellesta Holding Pte Ltd ("Wellesta") has been expanded. In addition to ...
-
Pollen Allergies, Hay Fever & IAQ Discussed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses pollen allergies, hay fever and IAQ. Allergic rhinitis is an allergic inflammation of the nasal airways that occurs when an allergen, such as pollen, is inhaled by an individual ...
-
Covid-19 or Seasonal Allergy: How to differentiate?
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you